Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vasopressins | 1 | 2017 | 372 | 0.580 |
Why?
|
| Perioperative Care | 3 | 2018 | 1067 | 0.570 |
Why?
|
| Intubation, Intratracheal | 4 | 2018 | 1312 | 0.560 |
Why?
|
| Plasma | 1 | 2017 | 573 | 0.500 |
Why?
|
| Vasoconstrictor Agents | 1 | 2017 | 631 | 0.500 |
Why?
|
| Erythrocyte Transfusion | 1 | 2017 | 519 | 0.460 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 1010 | 0.460 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 1478 | 0.400 |
Why?
|
| Anesthesia | 2 | 2018 | 1508 | 0.330 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 2274 | 0.320 |
Why?
|
| Intraoperative Complications | 3 | 2007 | 1192 | 0.280 |
Why?
|
| Anesthetics | 2 | 2021 | 525 | 0.250 |
Why?
|
| Awareness | 1 | 2007 | 597 | 0.230 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2018 | 1224 | 0.230 |
Why?
|
| Blood Pressure | 2 | 2017 | 8528 | 0.220 |
Why?
|
| Anesthesia, General | 2 | 2007 | 1093 | 0.210 |
Why?
|
| Southeastern United States | 1 | 2018 | 95 | 0.180 |
Why?
|
| Nevirapine | 1 | 1998 | 264 | 0.160 |
Why?
|
| Hepatic Encephalopathy | 1 | 1998 | 143 | 0.160 |
Why?
|
| Latex | 1 | 1996 | 61 | 0.150 |
Why?
|
| Duodenum | 1 | 2019 | 476 | 0.150 |
Why?
|
| Laminectomy | 1 | 2017 | 236 | 0.150 |
Why?
|
| Aneurysm, Ruptured | 1 | 2021 | 483 | 0.140 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 450 | 0.140 |
Why?
|
| Palpation | 1 | 1995 | 173 | 0.140 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 1998 | 611 | 0.140 |
Why?
|
| Rectum | 1 | 2019 | 887 | 0.130 |
Why?
|
| Monitoring, Intraoperative | 2 | 2017 | 959 | 0.130 |
Why?
|
| Blood Pressure Determination | 1 | 2017 | 607 | 0.120 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 1100 | 0.120 |
Why?
|
| Child Behavior Disorders | 1 | 1998 | 810 | 0.120 |
Why?
|
| Community Health Services | 1 | 2018 | 661 | 0.110 |
Why?
|
| Cardiovascular System | 1 | 2018 | 767 | 0.110 |
Why?
|
| Suicide | 1 | 2022 | 1558 | 0.100 |
Why?
|
| Intracranial Aneurysm | 1 | 2021 | 1342 | 0.100 |
Why?
|
| Mortality | 2 | 2018 | 2732 | 0.100 |
Why?
|
| Parent-Child Relations | 1 | 1994 | 769 | 0.090 |
Why?
|
| Spinal Fusion | 1 | 2017 | 1175 | 0.090 |
Why?
|
| Hypersensitivity | 1 | 1996 | 1019 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 1822 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2018 | 2019 | 0.080 |
Why?
|
| Anti-HIV Agents | 2 | 1998 | 4062 | 0.070 |
Why?
|
| Aortic Valve Stenosis | 1 | 1998 | 1832 | 0.070 |
Why?
|
| Child Development | 1 | 1998 | 2177 | 0.070 |
Why?
|
| Parents | 2 | 2022 | 3154 | 0.070 |
Why?
|
| Incidence | 3 | 2018 | 20320 | 0.070 |
Why?
|
| HIV Infections | 4 | 2019 | 15538 | 0.070 |
Why?
|
| Female | 17 | 2019 | 375205 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2020 | 71483 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2018 | 7763 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 13536 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 1998 | 4176 | 0.060 |
Why?
|
| Aged | 7 | 2018 | 161488 | 0.060 |
Why?
|
| Male | 16 | 2019 | 349524 | 0.050 |
Why?
|
| Humans | 21 | 2022 | 708843 | 0.050 |
Why?
|
| Hospitalization | 1 | 2020 | 9644 | 0.050 |
Why?
|
| Mental Recall | 1 | 2007 | 1195 | 0.050 |
Why?
|
| Prevalence | 1 | 2017 | 14712 | 0.050 |
Why?
|
| CD4-CD8 Ratio | 1 | 2019 | 114 | 0.050 |
Why?
|
| Middle Aged | 11 | 2018 | 213752 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2018 | 50597 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2020 | 15053 | 0.050 |
Why?
|
| Mid-Atlantic Region | 1 | 2018 | 24 | 0.040 |
Why?
|
| Thiopental | 1 | 1998 | 61 | 0.040 |
Why?
|
| Neuromuscular Depolarizing Agents | 1 | 1998 | 46 | 0.040 |
Why?
|
| Succinylcholine | 1 | 1998 | 64 | 0.040 |
Why?
|
| Escape Reaction | 1 | 1998 | 55 | 0.040 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 1999 | 247 | 0.040 |
Why?
|
| Infant | 7 | 2022 | 34261 | 0.040 |
Why?
|
| Aortic Coarctation | 1 | 1999 | 266 | 0.040 |
Why?
|
| Defense Mechanisms | 1 | 1998 | 180 | 0.040 |
Why?
|
| Blood | 1 | 2019 | 624 | 0.040 |
Why?
|
| Child, Preschool | 7 | 2022 | 41081 | 0.040 |
Why?
|
| Didanosine | 1 | 1996 | 157 | 0.040 |
Why?
|
| Time | 1 | 2018 | 526 | 0.040 |
Why?
|
| Pregnancy | 1 | 2017 | 26832 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 58184 | 0.040 |
Why?
|
| Dissociative Disorders | 1 | 1998 | 229 | 0.040 |
Why?
|
| Cardiac Output | 1 | 1998 | 904 | 0.040 |
Why?
|
| Bronchoscopes | 1 | 1995 | 59 | 0.040 |
Why?
|
| Fentanyl | 1 | 1998 | 392 | 0.040 |
Why?
|
| Isoflurane | 1 | 1998 | 368 | 0.030 |
Why?
|
| Anesthetics, Intravenous | 1 | 1998 | 405 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1908 | 0.030 |
Why?
|
| Sternum | 1 | 1995 | 165 | 0.030 |
Why?
|
| Ribavirin | 1 | 1996 | 396 | 0.030 |
Why?
|
| Educational Status | 1 | 2022 | 2278 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2021 | 61932 | 0.030 |
Why?
|
| Spinal Dysraphism | 1 | 1996 | 147 | 0.030 |
Why?
|
| Adolescent | 8 | 2022 | 84718 | 0.030 |
Why?
|
| Adult | 10 | 2020 | 211041 | 0.030 |
Why?
|
| Risk Factors | 2 | 2017 | 69553 | 0.030 |
Why?
|
| Anesthetics, Inhalation | 1 | 1998 | 555 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 14075 | 0.030 |
Why?
|
| Child | 8 | 2022 | 73636 | 0.030 |
Why?
|
| Patient Admission | 1 | 2020 | 1398 | 0.030 |
Why?
|
| Life Change Events | 1 | 1998 | 941 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 1998 | 933 | 0.030 |
Why?
|
| Infant, Newborn | 4 | 2022 | 24433 | 0.030 |
Why?
|
| Sex Distribution | 1 | 1998 | 2328 | 0.030 |
Why?
|
| Surface Properties | 1 | 1995 | 1209 | 0.030 |
Why?
|
| Arousal | 1 | 1998 | 1138 | 0.030 |
Why?
|
| Pressure | 1 | 1995 | 1242 | 0.030 |
Why?
|
| Cerebral Palsy | 1 | 1996 | 426 | 0.030 |
Why?
|
| Acyclovir | 1 | 1992 | 273 | 0.030 |
Why?
|
| Bronchi | 1 | 1995 | 845 | 0.030 |
Why?
|
| Vidarabine | 1 | 1992 | 348 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 1896 | 0.030 |
Why?
|
| Hypotension | 1 | 1996 | 822 | 0.030 |
Why?
|
| Poverty | 1 | 2022 | 2557 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1996 | 781 | 0.020 |
Why?
|
| Herpes Zoster | 1 | 1992 | 286 | 0.020 |
Why?
|
| Linear Models | 1 | 2019 | 5986 | 0.020 |
Why?
|
| Anaphylaxis | 1 | 1996 | 748 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 3070 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 5908 | 0.020 |
Why?
|
| Mast Cells | 1 | 1996 | 1601 | 0.020 |
Why?
|
| Hospitals | 1 | 2020 | 3290 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6766 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 1998 | 2022 | 0.020 |
Why?
|
| Equipment Design | 1 | 1995 | 3627 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 1998 | 2565 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 4383 | 0.020 |
Why?
|
| Heart Rate | 1 | 1998 | 4094 | 0.020 |
Why?
|
| Homeostasis | 1 | 1998 | 3334 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 1992 | 882 | 0.020 |
Why?
|
| Heart | 1 | 2018 | 4315 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 1998 | 3411 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 1996 | 2768 | 0.020 |
Why?
|
| Social Support | 1 | 1994 | 2119 | 0.020 |
Why?
|
| Meningitis, Viral | 1 | 1983 | 56 | 0.010 |
Why?
|
| Emotions | 1 | 1994 | 2413 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1998 | 8024 | 0.010 |
Why?
|
| Spinal Cord Ischemia | 1 | 1999 | 77 | 0.010 |
Why?
|
| HIV-1 | 1 | 1996 | 6757 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1994 | 3934 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1982 | 681 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 39292 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1995 | 19423 | 0.010 |
Why?
|
| Giant Cells | 1 | 1996 | 183 | 0.010 |
Why?
|
| Viremia | 1 | 1996 | 728 | 0.010 |
Why?
|
| Neuritis | 1 | 1992 | 37 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1996 | 1456 | 0.010 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1992 | 134 | 0.010 |
Why?
|
| Skin Diseases, Infectious | 1 | 1992 | 74 | 0.010 |
Why?
|
| Meningoencephalitis | 1 | 1992 | 85 | 0.010 |
Why?
|
| Brain | 1 | 1998 | 24969 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1982 | 2930 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1996 | 2543 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1996 | 2847 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1992 | 2303 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1996 | 6562 | 0.000 |
Why?
|
| Echovirus 9 | 1 | 1983 | 1 | 0.000 |
Why?
|
| Echovirus Infections | 1 | 1983 | 7 | 0.000 |
Why?
|
| Enterovirus B, Human | 1 | 1983 | 57 | 0.000 |
Why?
|
| Malta | 1 | 1982 | 5 | 0.000 |
Why?
|
| Coxsackievirus Infections | 1 | 1983 | 53 | 0.000 |
Why?
|
| Education, Special | 1 | 1983 | 85 | 0.000 |
Why?
|
| Adenovirus Infections, Human | 1 | 1983 | 70 | 0.000 |
Why?
|
| Enterovirus | 1 | 1983 | 65 | 0.000 |
Why?
|
| Brain Damage, Chronic | 1 | 1983 | 269 | 0.000 |
Why?
|
| Genetic Variation | 1 | 1996 | 6666 | 0.000 |
Why?
|
| Herpes Simplex | 1 | 1983 | 466 | 0.000 |
Why?
|
| Cost-Benefit Analysis | 1 | 1992 | 5235 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1992 | 11877 | 0.000 |
Why?
|
| Intelligence | 1 | 1983 | 895 | 0.000 |
Why?
|
| Disabled Persons | 1 | 1983 | 1154 | 0.000 |
Why?
|
| Pneumonia, Viral | 1 | 1992 | 3275 | 0.000 |
Why?
|
| Mothers | 1 | 1982 | 1991 | 0.000 |
Why?
|
| Sex Factors | 1 | 1982 | 10566 | 0.000 |
Why?
|
| Age Factors | 1 | 1982 | 18712 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 1983 | 39038 | 0.000 |
Why?
|
Concepts
(172)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(7)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_